Rally I dag, konkurspriset.
Kommer å gå fort nå.

Nå har de mer tid til å bli enige, for håpe det for selskapet sin skyld.
Men for aksjonærene ser det fortsatt ikke lyst mhp utvanning.

Er dagens aksjonærer heldige, så slipper de unna med 50 prosent emisjonsrabatt i forhold til dagens sluttkurs. Mitt tips i alle fall.

Det har sett mørkt ut en stund,i går var ett lyspunkt,time will tell,timing&volum gjelder i alle aksjer,nå settes nødemi på 8,gir 1/2 år å jobbe på👍

Er det rally hver dag i alle aksjer, Sabi ?

Ser ikke ut til at aksjonærene får være med på emisjonen, skal man tro møtet ref. som nettopp var:

The pre-emptive rights of the existing shareholders
under section 10-4 of the Private Limited Companies Act are set aside in
accordance with section 10-5 of the Private Limited Companies Act.

Ikke rare rabatten,når man blir vannet ut,og ikke får muligheten til å bli med.

SOFTOX satt i "penalty bench", blir det ekstra gebyrer å betale for dem pga dette ?
Hvor mange dager har de på seg, før Oslo børs vil stryke dette verdipapiret ?
Hvorfor klarer ikke SOFTOX å fullføre papirmøllen ? Er de redd for å vise tallene ?

Oslo Børs har satt Softox på Penalty Bench-listen
– En misforståelse, sier styreleder Geir Almås.

https://newsweb.oslobors.no/message/592865

Good position👍

Tror aksjonærene her at selskapet klarer å få "wound care" forbi fase III og regulatory approval,før de er tom for penger igjen innen utgangen av dette året ?
Graver selskapet sin egen grav,når de låner 12mill til 25% rente, og som i sin helhet skal innfries ila 2024 ? Dvs de må omsette for mye mer enn 12mill ila 2024, for at det skal gå.

ZERO SALG PÅ TOP 50
Oversikt for SOFTX (SOFTOX SOLUTIONS ). Oppdatert VPS 8.08.2023

01 NORDNET LIVSFORSIKRING AS 12.01% 9 067.2k 1 242k
02 HERMOD FARMS AS 7.16% 5 403.9k 740.3k
03 DINGE INVEST AS 6.93% 5 231.6k 716.7k
04 ALMÅS KRISTIAN 4.92% 3 715.7k 509k
05 PRO AS 3.29% 2 484.2k 340.3k
06 ALMHAUG BOLIG AS 3.00% 2 268.2k 310.7k
07 GH HOLDING AS 2.99% 2 260.6k 309.7k
08 SKOGBRYNET EIENDOM AS 2.49% 1 876.8k 257.1k
09 GEMALLO AS 2.41% 1 822k 249.6k
10 CS-HOLDING AS 1.90% 1 433.6k 196.4k
11 DANSKE BANK A/S 1.72% 1 297.7k 177.8k
12 WL-01 HOLDING AS 1.13% 854.1k 117k
13 AUBERT INVEST AS 1.10% 832.2k 114k
14 HOLTA & CO. AS 1.10% 832.2k 114k
15 NORDNET BANK AB 1.09% 824.96k 113k
16 FALCK FRÅS AS 1.00% 752.01k 103k
17 J G INVEST AS 0.96% 725.73k 99 415
18 SONJA OG EMIL AUBERTS LEGAT 0.88% 664.3k 91 000
19 ROCHA INVEST AS 0.87% 657k 90 000
20 OLSEN OTTAR 0.76% 571.88k 78 340 +2 450
21 JUVEN INGRID 0.68% 511k 70 000
22 SAND BJØRNAR LYNGVI 0.67% 508.08k 69 600
23 WENNBERG IVAN 0.58% 439.45k 60 198
24 ALSTAD INVEST AS 0.56% 423.4k 58 000
25 HOVIND SVENN IDAR FORBERGSKOG 0.56% 420.87k 57 653
26 NAVUS AS 0.53% 401.5k 55 000
27 HERNESS BJØRN 0.47% 351.42k 48 140
28 OSLO NÆRINGSUTVIKLING AS 0.46% 346.2k 47 425
29 DFL HOLDING AS 0.46% 346.09k 47 409
30 JOMAAS RUNE 0.43% 321.94k 44 101
31 IHLEN HELENE KRISTINE 0.41% 306.6k 42 000
32 LINDVARD INVEST AS 0.41% 306.6k 42 000
33 LITLESKARE KENNETH 0.40% 300.2k 41 123
34 HAREFRØKEN INVEST AS 0.39% 294.65k 40 363
35 RAVI INVESTERING AS 0.39% 292k 40 000
36 JOHANSEN ØYVIND HESTVIK 0.37% 277.4k 38 000
37 L B HOLDING AS 0.35% 262.8k 36 000
38 JONASSEN ULF EUGEN 0.34% 257.4k 35 260
39 HAUGSTAD JAN AMUND 0.33% 249.32k 34 154
40 BENSVIK KYSTFISKE AS 0.33% 248.27k 34 010
41 BØRSELIEN MARIUS 0.33% 248.2k 34 000
42 KOMMODE HOLDING AS 0.32% 245.28k 33 600
43 FOSS TORGEIR 0.31% 230.92k 31 633
44 SKJERSETH DANIEL NERLAND 0.30% 226.3k 31 000
45 HANDELAND ØYVIND 0.29% 219.02k 30 003
46 LUNGOCI CECILIA-ADRIANA 0.28% 212.94k 29 170
47 SOLVIDA AS 0.28% 209.41k 28 686
48 ARUMUGAM KYLE 0.27% 204.43k 28 004
49 HANSETH JOHNNY 0.27% 200.75k 27 500
50 KRISTIANSEN BEN MAGNE 0.26% 197.91k 27 111
51 Other investors 30.28% 22.86m 3 130.88k -2 150

Nå er jo ikke volumet all verden så de litt høyere oppe ville jo bruke en halv evighet på å selge seg ned/ut, men fair enough at noen ikke lemper ut er jo positivt.

https://www.nettavisen.no/nyheter/who-og-usa-overvaker-ny-type-svart-mutert-koronavirus/s/5-95-1272046

På tide med en reality-check for Softox aksjeeiere .... advarte mot selskapet gjentatte ganger i 2020 og 2021. Se nå utviklingen hvor aksjen er ned 92,67% siste 3 år....

https://e24.no/bors/instrument/SOFTX.MERK

Skulle ikke q3 rap komme idag?

https://www.finansavisen.no/finans/2023/11/01/8053205/softox-solutions-blor-penger-stanser-prosjekter?fbclid=IwAR3q1n9DSGhPdLj7vfQZ5kieDQ_MOU2_OOv-qRIWzuwoh6GUYtHCb7QOpgg

https://newsweb.oslobors.no/message/602773

Er en tragedie dette selskapet.

Oversikt for SOFTX (SOFTOX SOLUTIONS ). Oppdatert VPS 2.01.2024


01 NORDNET LIVSFORSIKRING AS 13.01% 4 522.7k 1 396k Pluss ++ 12 071
02 HERMOD FARMS AS 6.90% 2 398.4k 740.3k
03 DINGE INVEST AS 6.68% 2 322k 716.7k
04 PRO AS 3.41% 1 183.6k 365.3k
05 GH HOLDING AS 2.89% 1 003.3k 309.7k
06 ALMHAUG BOLIG AS 2.85% 990.52k 305.7k
07 GEMALLO AS 2.56% 889.66k 274.6k
08 ALMÅS KRISTIAN 2.41% 839.16k 259k
09 SKOGBRYNET EIENDOM AS 2.40% 833k 257.1k
10 ALMÅS DINA KRISTINE AARSVOLD 1.96% 680.4k 210k
11 CS-HOLDING AS 1.83% 636.27k 196.4k
12 DANSKE BANK A/S 1.76% 612.24k 189k
13 HERNESS BJØRN 1.75% 609.19k 188k Pluss ++ 10 000
14 OLSEN OTTAR 1.37% 476.13k 147k Pluss ++ 4 490
15 OSLO NÆRINGSUTVIKLING AS 1.14% 396.66k 122.4k
16 NORDNET BANK AB 1.12% 388.44k 119.9k -918
17 WL-01 HOLDING AS 1.09% 379.08k 117k
18 FALCK FRÅS AS 0.96% 333.77k 103k
19 HAREFRØKEN INVEST AS 0.96% 333.28k 102.9k
20 ROCHA INVEST AS 0.84% 291.6k 90 000
21 JUVEN INGRID 0.65% 226.8k 70 000
22 ALMÅS INGEBORG VICTORIA AARSVOLD 0.61% 212.22k 65 500
23 AUBERT INVEST AS 0.60% 207.36k 64 000
24 HOLTA & CO. AS 0.60% 207.36k 64 000
25 WENNBERG IVAN 0.56% 195.04k 60 198
26 HOVIND SVENN IDAR FORBERGSKOG 0.54% 186.8k 57 653
27 WL-02 HOLDING AS 0.53% 182.88k 56 444
28 NAVUS AS 0.51% 178.2k 55 000
29 ROCHA ANDERS MARCEL DA 0.51% 176.58k 54 500 pluss++ 3 500
30 SOLVIDA AS 0.48% 167.75k 51 775
31 SONJA OG EMIL AUBERTS LEGAT 0.48% 165.24k 51 000
32 LITLESKARE KENNETH 0.47% 164.16k 50 667 pluss++ 5 400
33 DFL HOLDING AS 0.44% 153.61k 47 409
34 LUNDBY IRENE 0.43% 149.81k 46 237
35 SAND BJØRNAR LYNGVI 0.43% 147.95k 45 663
36 NILSEN SIMEN NESTOR 0.42% 145.8k 45 000
37 JOMAAS RUNE 0.41% 142.89k 44 101
38 BØRSELIEN MARIUS 0.41% 142.56k 44 000
39 IHLEN HELENE KRISTINE 0.39% 136.08k 42 000
40 LINDVARD INVEST AS 0.39% 136.08k 42 000
41 RAVI INVESTERING AS 0.37% 129.6k 40 000
42 KOMMODE HOLDING AS 0.37% 129.11k 39 850
43 JOHANSEN ØYVIND HESTVIK 0.35% 123.12k 38 000
44 BØRSELIEN HELGE STEINAR 0.34% 119.88k 37 000 pluss ++5 910
45 L B HOLDING AS 0.34% 116.64k 36 000
46 BENSVIK KYSTFISKE AS 0.32% 110.19k 34 010
47 HOANG NAM TIEN 0.30% 105.53k 32 570
48 FOSS TORGEIR 0.29% 102.49k 31 633
49 ARUMUGAM KYLE 0.29% 100.45k 31 004
50 LARSEN RONNY 0.29% 99 614 30 745 INN
51 Other investors 29.00% 10.08m 3 112.25k -36 234

TOP 50 øker med 52 528 aksjer.
Oversikt for SOFTX (SOFTOX SOLUTIONS ). Oppdatert VPS 4.01.2024

01 NORDNET LIVSFORSIKRING AS 13.48% 5 350.6k 1 446k ++23 901
02 HERMOD FARMS AS 6.90% 2 739k 740.3k
03 DINGE INVEST AS 6.68% 2 651.6k 716.7k
04 PRO AS 3.41% 1 351.6k 365.3k
05 GH HOLDING AS 2.89% 1 145.8k 309.7k
06 ALMHAUG BOLIG AS 2.85% 1 131.1k 305.7k
07 GEMALLO AS 2.56% 1 016k 274.6k
08 ALMÅS KRISTIAN 2.41% 958.3k 259k
09 SKOGBRYNET EIENDOM AS 2.40% 951.27k 257.1k
10 ALMÅS DINA KRISTINE AARSVOLD 1.96% 777k 210k
11 CS-HOLDING AS 1.83% 726.61k 196.4k
12 HERNESS BJØRN 1.75% 695.69k 188k
13 DANSKE BANK A/S 1.74% 691.76k 187k
14 OLSEN OTTAR 1.52% 601.87k 162.7k ++15 713
15 OSLO NÆRINGSUTVIKLING AS 1.14% 452.97k 122.4k
16 WL-01 HOLDING AS 1.09% 432.9k 117k
17 NORDNET BANK AB 1.09% 431.26k 116.6k
18 FALCK FRÅS AS 0.96% 381.16k 103k
19 HAREFRØKEN INVEST AS 0.96% 380.59k 102.9k
20 ROCHA INVEST AS 0.84% 333k 90 000
21 JUVEN INGRID 0.65% 259k 70 000
22 ALMÅS INGEBORG VICTORIA AARSVOLD 0.61% 242.35k 65 500
23 AUBERT INVEST AS 0.60% 236.8k 64 000
24 HOLTA & CO. AS 0.60% 236.8k 64 000
25 WENNBERG IVAN 0.56% 222.73k 60 198
26 ROCHA ANDERS MARCEL DA 0.56% 221.63k 59 900 ++5 400
27 HOVIND SVENN IDAR FORBERGSKOG 0.54% 213.32k 57 653
28 LUNDBY IRENE 0.53% 209.74k 56 687 ++10 450
29 WL-02 HOLDING AS 0.53% 208.84k 56 444
30 NAVUS AS 0.51% 203.5k 55 000
31 SOLVIDA AS 0.48% 191.57k 51 775
32 SONJA OG EMIL AUBERTS LEGAT 0.48% 188.7k 51 000
33 LITLESKARE KENNETH 0.47% 187.47k 50 667
34 DFL HOLDING AS 0.44% 175.41k 47 409
35 SAND BJØRNAR LYNGVI 0.43% 168.95k 45 663
36 NILSEN SIMEN NESTOR 0.42% 166.5k 45 000
37 JOMAAS RUNE 0.41% 163.17k 44 101
38 BØRSELIEN MARIUS 0.41% 162.8k 44 000
39 IHLEN HELENE KRISTINE 0.39% 155.4k 42 000
40 LINDVARD INVEST AS 0.39% 155.4k 42 000
41 RAVI INVESTERING AS 0.37% 148k 40 000
42 KOMMODE HOLDING AS 0.37% 147.44k 39 850
43 JOHANSEN ØYVIND HESTVIK 0.35% 140.6k 38 000
44 BØRSELIEN HELGE STEINAR 0.34% 136.9k 37 000
45 L B HOLDING AS 0.34% 133.2k 36 000
46 BENSVIK KYSTFISKE AS 0.32% 125.84k 34 010
47 HOANG NAM TIEN 0.30% 120.51k 32 570
48 FOSS TORGEIR 0.29% 117.04k 31 633
49 ARUMUGAM KYLE 0.29% 114.71k 31 004
50 LARSEN RONNY 0.29% 113.76k 30 745
51 Other investors 28.27% 11.22m 3 032.79k -52 528

Spennende. Når kommer FDA godkjenning i US sammen med det amerikanske forsvaret? Europeiske Forsvaret? Kan 2024 bli et år med gjennombrudd? Nå er aksjen konkurspriset.

https://newsweb.oslobors.no/message/608157

Det "nye" Softox starter nå :)

Det nye Softox starter vel med en emisjon på 1 krone, eller enda lavere enn det?

Det nye SoftOx kan nok bli bra på sikt men selskapet trenger penger og da kommer nok en emisjon. Tror emisjonskursen blir under kr 1, andre synspunkter?

Oversikt for SOFTX (SOFTOX SOLUTIONS ). Oppdatert VPS 16.01.2024 - liten bevegelse. Ikke glem at avtalen med kreditorene( gjeldskonvertering ) pluss warrants etc er på 8 kr og ikke 2 kr :) signert i sommer. Dagens markedsverdi på 20 mill er alt for lav.
https://www.finansavisen.no/helse/2023/06/09/8014415/softox-solutions-har-inngatt-avtale-med-kreditorene
https://newsweb.oslobors.no/message/592865

01 NORDNET LIVSFORSIKRING AS 13.23% 2 787.9k 1 419k -5 699
02 HERMOD FARMS AS 6.90% 1 454.6k 740.3k
03 DINGE INVEST AS 6.68% 1 408.2k 716.7k
04 PRO AS 3.41% 717.81k 365.3k
05 GH HOLDING AS 2.89% 608.51k 309.7k
06 ALMHAUG BOLIG AS 2.85% 600.73k 305.7k
07 GEMALLO AS 2.56% 539.56k 274.6k
08 ALMÅS KRISTIAN 2.41% 508.94k 259k
09 SKOGBRYNET EIENDOM AS 2.40% 505.2k 257.1k
10 ALMÅS DINA KRISTINE AARSVOLD 1.96% 412.65k 210k
11 HERNESS BJØRN 1.83% 386.72k 196.8k
12 CS-HOLDING AS 1.83% 385.89k 196.4k
13 OLSEN OTTAR 1.76% 371.89k 189.3k
14 DANSKE BANK A/S 1.76% 371.88k 189.3k
15 NORDNET BANK AB 1.16% 245.04k 124.7k ++4 941
16 OSLO NÆRINGSUTVIKLING AS 1.14% 240.57k 122.4k
17 WL-01 HOLDING AS 1.09% 229.91k 117k
18 FALCK FRÅS AS 0.96% 202.42k 103k
19 HAREFRØKEN INVEST AS 0.96% 202.13k 102.9k
20 ROCHA INVEST AS 0.84% 176.85k 90 000
21 ROCHA ANDERS MARCEL DA 0.69% 145.41k 74 000
22 JUVEN INGRID 0.65% 137.55k 70 000
23 ALMÅS INGEBORG VICTORIA AARSVOLD 0.61% 128.71k 65 500
24 AUBERT INVEST AS 0.60% 125.76k 64 000
25 HOLTA & CO. AS 0.60% 125.76k 64 000
26 WENNBERG IVAN 0.56% 118.29k 60 198
27 HOVIND SVENN IDAR FORBERGSKOG 0.54% 113.29k 57 653
28 LUNDBY IRENE 0.53% 111.39k 56 687
29 WL-02 HOLDING AS 0.53% 110.91k 56 444
30 NAVUS AS 0.51% 108.08k 55 000
31 SOLVIDA AS 0.48% 101.74k 51 775
32 SONJA OG EMIL AUBERTS LEGAT 0.48% 100.22k 51 000
33 LITLESKARE KENNETH 0.47% 99 561 50 667
34 DFL HOLDING AS 0.44% 93 159 47 409
35 NILSEN SIMEN NESTOR 0.42% 88 425 45 000
36 JOMAAS RUNE 0.41% 86 658 44 101
37 BØRSELIEN MARIUS 0.41% 86 460 44 000
38 IHLEN HELENE KRISTINE 0.39% 82 530 42 000
39 LINDVARD INVEST AS 0.39% 82 530 42 000
40 SAND BJØRNAR LYNGVI 0.38% 81 003 41 223
41 RAVI INVESTERING AS 0.37% 78 600 40 000
42 KOMMODE HOLDING AS 0.37% 78 305 39 850
43 INNSELSET-SMIDTSRØD SANDER 0.37% 77 126 39 250
44 JOHANSEN ØYVIND HESTVIK 0.35% 74 670 38 000
45 BØRSELIEN HELGE STEINAR 0.34% 72 705 37 000
46 L B HOLDING AS 0.34% 70 740 36 000
47 BENSVIK KYSTFISKE AS 0.32% 66 830 34 010
48 HOANG NAM TIEN 0.31% 65 955 33 565
49 FOSS TORGEIR 0.29% 62 159 31 633
50 ARUMUGAM KYLE 0.29% 60 923 31 004
51 Other investors 27.91% 5 881.22k 2 993.45k 17 641

Denne bør vel stikke over 4 - 5 snart.

Du vet 50 % ned er 100 % opp :) ryker 2,40-2,50 så er det 4 next

For nøyaktig 1 år siden var kursen 27.40 så her er det mye å gå på. Lasting på 2 tallet må da være bra - https://finance.yahoo.com/quote/SOFTX.OL/history?p=SOFTX.OL

BOOOOM! NEWS da blir selskapet gjeldsfritt! Konverteringskursen på dette lånet ER 8 kr pr aksje ! https://www.finansavisen.no/helse/2023/06/09/8014415/softox-solutions-har-inngatt-avtale-med-kreditorene

Tydelig at Softox frister øretrillerne nå ja. Har blitt en jalla-aksje. Lite relevant å sammenligne med tidligere kurser. Selskapet er tom for penger. Så her kan det bli 0 i verste fall, eller utvanning i mer eller mindre grad hvis de får med noen til å satse...Perfekt for trading ja.

Fantastiske nyheter i dag :) Det er ikke lenger før vi blåser over 4 igjen. HOLD på aksjene.

Fint nok at de kjøper seg litt tid til 25% rente og at de kun bruker 1 mill pr mnd. Tilsier at de utsetter problemet 1 år hadde det ikke vert for at noen skal ha penger innen utgangen av juni og september. Får de på plass inntekter så er det ikke noe problem men de har jo snakket om inntekter mange ganger før så er kanskje ikke så rart at interessen for selskapet er på et lavmål.

Kanskje du får rett. Kan bli en fin reise fremover

Går veien dette, kommer å se,10 snart.

OSLO - 8th of January 2024:

Through 2023, SoftOx Solutions (SoftOx) has restructured the entire business, as a consequence of a cost base that was too high and an
operating model that was not optimal. Following this operational restructuring, SoftOx has now initiated a process of evaluating different financing alternatives.
SoftOx's patent-protected technology has shown an excellent ability to contribute to solving some of the world's biggest health challenges, such as antimicrobial
resistance and viral infections in the lungs and in wounds. "If we succeed developing SoftOx technology for wound and respiratory care, it will be an alternative to
today's antibiotic in more than 50% of the cases which lead to death from Antimicrobial Resistance in 2019", says Professor Thomas Bjarnsholt, Chief Scientific Officer
of SoftOx Solutions AS.
"Despite the fact that last year was a tough year for SoftOx, several positive actions can be highlighted. The strategy for the new SoftOx shall soundly develop the SoftOx
technology going forward and enhance shareholder value. With a clear strategy for bringing products to market and continued research & development over the next 2-3 years, our ambition is to deliver results that will confirm a significant value
potential within Wound Care, at the same time as secured funding from the European Defence Fund (EDF) will further develop SoftOx Inhalation Solutions (SIS)", says Geir
Almaas, executive Chairman of SoftOx Solutions.
The strategy depends on successful financial restructuring of the company, including a solution to the company's convertible debt of about NOK 67 million.
The following progress has been made during 2023:
Changed Business Model:
- Established a small and effective organization reducing cost base by 70%:
- Outsourced product development for SIS and EDF.
- Prepared a drop down of Wound & Skin care to become a separate company
covering its own cost.
- Achieved a sufficient reduction in the short-term unsecured debt.
New Research & Development results:
- Next Generation SoftOx technology: The next generation technology will have
highly improved stability, even with high concentrations. An abstract of
SoftOx Next Generation technology was presented at the US Military Health
System Research Symposium in Florida in August.
- Biofilm removal: Research results from use of SoftOx technology in dental health show a unique ability to remove oral biofilm, to prevent and treat periodontitis.
Customer acceptance and distribution agreement
- Talks with major international players on distribution of animal
health products worldwide, and distribution of human wound rinse in Europe.
"New SoftOx" - Going forward the next two-three years
The new cost-effective business model, promising results from Next Generation
technology, and additional research results, create the foundation for the strategy going forward.
Next Generation SoftOx technology - stable solutions at higher concentrations
SoftOx' clinical studies in wounds have shown that the human body is tolerant of higher doses of the active ingredient hypochlorous acid than was originally
anticipated. With the purpose of developing this next generation of SoftOx technology an industrial
PhD program was established at the Department of Pharmacy at the University of Oslo.
An abstract of Next Generation SoftOx was presented at the US Military Health System
Research Symposium in Florida in August 2023. Patent pending, filed Autumn 2022.
Strategically, this technological leap means that SoftOx considers itself to have leading technology for products based on hypochlorous acid. This new technology enables the development of products with higher efficacy and longer shelf-time than what we see in the market today. Inhalation The EDF/COUNTERACT project has synergies to the development of SoftOx Next Generation
Inhalation solution for the civilian market. The EDF project Phase I aims at regulatory bridging on API (Active Pharmaceutical Ingredient) and finding the maximum tolerated dose in humans. "The synergies between the military development program and
the civilian development are clear, and the market potential is great. Hopefully we will be able to achieve grants from future EDF-programs for phase 2 and 3 when we have
successfully finished the program that has already been funded through EDF/COUNTERACT"
says Christian Harstad, Interim CEO SoftOx Solutions.
- Inhalation Military: Research and development continue, funded by the
EDF/COUNTERACT program until Phase I study (Maximum Tolerated Dose) is completed in 2025.
- Inhalation Civilian: Civilian development of the inhalation project
will require NOK 30 million in separate funding for a Phase II study
(Proof of Concept for hospital acquired pneumonia (HAP)). To avoid
double work and to keep required capital at a minimum, the company
plans to conduct this Phase II study when we have maximum tolerated dose data from the EDF/COUNTERACT studies. These data will be available late 2025.
In 2023 SoftOx entered into an agreement with the University of Copenhagen for the
development of the company's unique technology, where SoftOx outsource its research and product development to the University of Copenhagen.
"University of Copenhagen has some of the best scientists in the world within the field of antimicrobial resistance and infections. Together we will establish new and innovative solutions for fighting infections in the respiratory system", says
Harstad. During 2024, the company intends to continue the work to separate the Wound and Skin care business into a separate company. As a basis for this work, in February 2023,
SoftOx obtained an external valuation of the wound technology as a stand-alone technology, which estimated a "fair market value" of the technology of approximately NOK 2.1
billion (USD 200 million)at that time, with significant value upside after successful completion of Phase II study.
It was a severe setback for the company when the American health authorities, FDA in January 2023 rejected the company's application to register SoftOx Wound Rinse as a
Medical Device class 2 in the USA. The reason for rejection was insufficient clinical documentation.
"We had large international distributors ready to distribute SoftOx Wound Rinse and we
had built up production facilities at Fornebu. With production and distribution in place, together with excellent clinical results, SoftOx Wound and Skin care would have
been ready for sale or separate listing. Following this experience, we have decided to cooperate with leading partners instead of trying to do everything ourselves", says Almaas.
Establish a new SoftOx Wound and Skin company
We have considered several solutions for Wound and Skin care, including discussions of merger with a specific NASDAQ NY listed company where SoftOx should keep approximately.
85% of the shares in the merged company. After careful considerations, SoftOx concluded that before seeking a listing, SoftOx should receive further clinical data.
SoftOx has therefore chosen a model where we first establish Wound and Skin care as a non-listed company and prepare it for either future sale or listing.
The strategy for the new Wound and Skin company will be:
- Finance the new company with separate funding of about EUR 10 million.
- Achieve regulatory approval of Medical Device wound cleanser in Europe
and US.
- Perform Phase 2 for SoftOx Biofilm Eradicator (SBE):
- The estimated probability of success is statistically over 80%.
- According to the company's expectations the estimated value will increase significantly after finish a successful phase 2 study on SBE.
- Establish an outsourced production for both first - and next generation technology.
- Through partners and distributors, bring products to market within
animal health care, human wound health care, oral health care and skin disinfection.
- Within two to three years list/sell the Wound and Skin care company on a relevant international market. If successful, Wound and Skin care can finance further development of SIS or be used to pay dividends to shareholders.

Due to the fact that the SoftOx Wound Care Technology Valuation Guidance was
prepared for a different purpose nearly a year ago, it can be in risk of
misguiding the investor when published today, KWC AS have therefore kindly asked
SoftOx to republish the stock notes without including the guidance as attachment. For the company the purpose for the publication was to give the
market relevant tools and information to independently consider the value potential of the wound care technology, but we understand and respect KWC's
request.


Dette er noe av The New Softox som vil komme

Tror det går raskt opp til 4 kr fremover

Nå er lån sikkert 88% 40mill. Kan bli en rask dobling

4 er lite min venn 27.40 16 januar 2023. Produktet har milliard potensiale. Bare patentet må da ha en verdi på 250 mill.

Nå kommer griseemisjonen.....